[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355330-105":59,"doc-detail-355330-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-the-chemokine-treg-axes-in-tumor-immune-evasion-from-mechanisms-to-therapeutic-opportunities","Targeting the chemokine-Treg axes in tumor immune evasion - from mechanisms to therapeutic opportunities","","Cancer immunotherapy reshapes oncology but is constrained by immune evasion within the tumor microenvironment (TME). Regulatory T cells (Tregs) suppress effector T-cell proliferation and activation and are enriched in many solid tumors, where higher levels link to poor prognosis, invasiveness, and resistance. A key enrichment mechanism is the chemokine-chemokine receptor axis: tumor and stromal cells secrete CCL22, CCL20, and CXCL12 to recruit Tregs via CCR4, CCR6, and CXCR4. This mini review consolidates eight experimentally validated axes (2005–2025) and highlights receptor blockade, checkpoint inhibitor combinations, and omics approaches to reprogram the TME and identify biomarkers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-chemokine-treg-axes-in-tumor-immune-evasion-from-mechanisms-to-therapeutic-opportunities/355330/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-chemokine-treg-axes-in-tumor-immune-evasion-from-mechanisms-to-therapeutic-opportunities/355330.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why do regulatory T cells (Tregs) limit cancer immunotherapy outcomes?","Question",{"text":113,"@type":114},"Tregs potently inhibit effector T-cell proliferation and activation, dampening antitumor immune responses and supporting an immunosuppressive tumor microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the chemokine-chemokine receptor axis recruit Tregs to the TME?",{"text":118,"@type":114},"Tumor and stromal cells secrete chemokines such as CCL22, CCL20, and CXCL12, which bind to CCR4, CCR6, and CXCR4 on Tregs to drive recruitment and activation in the TME.",{"name":120,"@type":111,"acceptedAnswer":121},"What therapeutic strategies are discussed for targeting these axes?",{"text":122,"@type":114},"Strategies include selective receptor blockade, combining chemokine-axis targeting with immune checkpoint inhibitors, and omics-based approaches to address Treg heterogeneity and improve antitumor immunity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355330,1790154548,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Mini Review  \nPUBLISHED 11 March 2026  \nDOI 10.3389/fimmu.2026.1779388  \nOPEN ACCESS  \nEDITED BY  \nAnurag Sharma,  \nManipal University Jaipur, India  \nREVIEWED BY  \nTom Van Loy,  \nKU Leuven, Belgium  \n*CORRESPONDENCE  \nXuanfen Zhang  \n [zhang_xf@lzu.edu.cn](zhang_xf@lzu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 01 January 2026  \nREVISED 20 January 2026  \nACCEPTED 23 February 2026  \nPUBLISHED 11 March 2026  \nCITATION  \nLian C, Liu L and Zhang X (2026)  \nTargeting the chemokine-Treg axes in tumor immune evasion:  \nfrom mechanisms to therapeutic opportunities.  \nFront. Immunol. 17:1779388 .  \ndoi: 10.3389/fimmu.2026.1779388  \nCOPYRIGHT  \n© 2026 Lian, Liu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeting the chemokineTreg axes in tumor immune evasion: from mechanisms to therapeutic opportunities  \nChao Lian 1,2†, Ling Liu 3† and Xuanfen Zhang 1*  \n1 Department of Plastic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China, 2 Department of Plastic and Aesthetic Surgery, Changzhi People’s Hospital, The Afﬁliated Hospital of Changzhi Medical College, Changzhi, Shanxi, China, 3 Department of Reproductive Medicine, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China  \nCancer immunotherapy has transformed oncology, yet its clinical efﬁcacy is often limited by immune evasion within the tumor microenvironment (TME) . Regulatory T cells (Tregs), a key immunosuppressive lineage, potently inhibit effector T-cell proliferation and activation, thereby dampening antitumor immune responses. Tregs are frequently enriched in diverse solid tumors, and their abundance correlates with poor prognosis, increased tumor invasiveness, and therapeutic resistance. A major mechanism driving this enrichment is the chemokinechemokine receptor axis. Tumor cells, along with other stromal and immune cells in the TME, secrete chemokines including CCL22, CCL20, and CXCL12, which bind to CCR4, CCR6, and CXCR4 on Tregs and direct their recruitment and activation within the TME. This establishes an immunosuppressive niche that promotes tumor growth, facilitates metastasis, and reduces responsiveness to immunotherapy. This review consolidates eight experimentally validated chemokine-Treg axes from 2005 to 2025, with each study annotated by tumor type and represented by the highest observed level of evidence. A systematic representation illustrates how these axes mediate Treg-driven immunosuppression and maps their prevalence across cancers. Focusing on these axes provides mechanistic insights, highlights potential therapeutic targets, and identiﬁes predictive biomarkers. Strategies targeting the chemokine-chemokine receptor axes, including selective receptor blockade, combination with immune checkpoint inhibitors, and omics-based approaches to resolve Treg heterogeneity, offer avenues to reprogram the immunosuppressive TME and enhance antitumor immunity.  \nKEYWORDS  \ncancer immunotherapy, chemokine receptors, chemokines, immune evasion, regulatory T cells, tumor microenvironment  \n1 Introduction  \nThe advent of cancer immunotherapy marks a transformative milestone in oncology. Unlike traditional therapies that directly target tumor cells, immunotherapy harnesses the immune system to eliminate malignancies. By coordinating the activation of T cells and other immune effectors, it aims to mount a robust antitumor response (1) . Clinical outcomes of cancer patients critically depend on the ability of immune cells to recognize  \nFrontiers in","cbCair3E7Nak74df","https://ap.wps.com/l/cbCair3E7Nak74df","pdf",1928641,"English","# Key concepts in tumor immune evasion\n## Regulatory T cells (Tregs) and prognosis\n## Chemokine-chemokine receptor axis\n# Cellular orchestrators of tumor immune suppression","[{\"question\":\"Why do regulatory T cells (Tregs) limit cancer immunotherapy outcomes?\",\"answer\":\"Tregs potently inhibit effector T-cell proliferation and activation, dampening antitumor immune responses and supporting an immunosuppressive tumor microenvironment.\"},{\"question\":\"How does the chemokine-chemokine receptor axis recruit Tregs to the TME?\",\"answer\":\"Tumor and stromal cells secrete chemokines such as CCL22, CCL20, and CXCL12, which bind to CCR4, CCR6, and CXCR4 on Tregs to drive recruitment and activation in the TME.\"},{\"question\":\"What therapeutic strategies are discussed for targeting these axes?\",\"answer\":\"Strategies include selective receptor blockade, combining chemokine-axis targeting with immune checkpoint inhibitors, and omics-based approaches to address Treg heterogeneity and improve antitumor immunity.\"}]","Targeting the chemokine-Treg axes in tumor immune evasion - from mechanisms to therapeutic opportunities | PDF",1790117812,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0488b5e57a6f67d060aa13c6b2aa0c5e.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf73241135e4e7ae69a7093cfa8fb662.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af100d55fd18a629713977e6918a3c3a.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56d02c768dfa6a4636f6166c7f41777f.webp",980,1385]